NAME OF METHODS MODE OF REACTION PRINCIPLE PROCEDURE OF MEASUREMENT CONVE REFERENCE RANGE CLINICAL

ANALYTE REACTION R SIGNIFICANCE

SION
FACTO
R
CARBOHYDRATES
Glucose Hexokinase Endpoint 0.0555 Diagnosis and
1 monitoring of
treatment in
diabetes
mellitus.

PROTEINS
Total Protein Biuret Endpoint 10 Detection of
defective
protein
synthesis in
the liver,
protein loss
due to
impaired
kidney
function,
intestinal
malabsorption
or
nutritional
deficiency,
chronic
inflammatory
disorders, liver
cirrhosis and
dehydration.
 NONPROTEIN NITROGENS
Urea UV, GLDH 2 Point 0.1665 Performed to
Kinetic differentiate
(fixed between pre-
time) renal and
postrenal
azotemia.

Uric Acid Enzymatic Endpoint 59.48 Determination

(uricase) of gout, renal
diseases, and
coronary heart
disease
Creatinine Modified 2 Point 88.4 Enables
Jaffe- Kinetic estimation of
Kinetic (fixed the glomerular
time) filtration rate
which allow
better
detection of
kidney
diseases and
monitoring of
renal function

Ammonia UV 2 Point 58.71 Diagnosis and

Kinetic prognosis of
(fixed Reye’s
time) Syndrome,
coma
associated
with hepatic
dysfunction
caused by
cirrhosis and
neoplasms.
LIPOPROTEIN
Triglyceride Endpoint 0.0112 Screening of
6 the lipid
status to
detect
atheroscleroti
c risks and in
monitoring of
lipid
lowering
 measure
Cholesterol Endpoint 0.0258 Determination
6 of the
individual total
cholesterol
(TC) level is
used for
screening
purposes
while for a
better risk
assessment it
is necessary to
measure
additionally
HDL-
Cholesterol
and LDL-
Cholesterol.
Cholesterol Endpoint 0.0258 Used to
HDL 6 measure HDL-
Cholesterol
and LDL-
Cholesterol.

LIVER PANEL
Bilirubin Auto Direct Endpoint 17.1

Bilirubin Auto Total Endpoint 17.1

Bilirubin Jendrassik Endpoint 17.1 Provide
& Grof measurement
of total
bilirubin.

Glutamate Modified Kinetic 0.0166 Increased level

Oxaloacetate IFCC 7 determines
Transaminase damages of
(AST) heart or
skeletal
muscle as well
as of liver
parenchyma.
Parallel
measurement
of GPT
and GOT is
therefore
applied to
distinguish
liver from
heart or
skeletal
muscle
damages. The
GOT/GPT ratio
is used for
 differential
diagnosis in
liver diseases
Glutamic Modified Kinetic 0.0166 Liver specific
Pyruvic IFCC 7 enzyme which
Transaminase only elevates
(ALT) in
hepatobiliary
diseases.
Parallel
measurement
of GPT
and GOT is
therefore
applied to
distinguish
liver from
heart or
skeletal
muscle
damages. The
GOT/GPT ratio
is used for
differential
diagnosis in
liver diseases
Alkaline Modified Kinetic 0.0166
Phosphatase IFCC 7
(ALP)

Gamma SZASZ, Kinetic 0.0166

Glutamyl standardiz 7
Transferase ed to IFCC
(GGT)
Lactate UV, IFCC Kinetic 0.0166 Determination
dehydrogena 7 of pathological
se (LDH) conditions
such as
myocardial
infarction,
cancer,
diseases of
liver, blood or
muscle.